top of page
Unbranded infant formula tins on a modern production line with export logistics in the background

a2 Milk China Formula Sales Recover to Half Their Previous Level

Writer: AgriLinkage Food
AgriLinkage Food
8 minutes ago
4 min read

The a2 Milk Company says sales of its China label infant formula have recovered to about half the level recorded before a supply disruption, up from roughly 40 percent in August. The improvement is real, but it also shows how far the business remains from restoring normal demand in its most important market.


The company disclosed the update on 19 November 2026 in an official market release. It said product shortages during the fourth quarter of its 2026 financial year reduced availability and pushed many existing users toward competing brands. That customer loss is expected to continue affecting sales during the current financial year.


Supply is returning faster than customers


Infant formula is a repeat purchase category built on trust, availability and a child's acceptance of a product. When shelves or online channels run short, parents cannot always wait for supply to recover. A switch made during a shortage can become permanent if the replacement product remains available and performs as expected.


That is why a recovery to 50 percent of the former sales rate should not be read as a simple production restart. It measures product movement in the market, not just cans leaving a factory. The rise from 40 percent in August suggests better availability and some returning demand, while the remaining gap shows the commercial cost of losing continuity in a sensitive consumer category.


The company also said English label formula sales were indirectly affected by its May 2026 recall of a small volume of product carrying labels for the United States. It did not report a new recall in the latest update. The current issue is the pace of demand recovery after earlier supply and reputation pressures.


Formula sales may remain flat even as the group grows


a2 Milk now expects total infant formula sales in the 2027 financial year to be broadly similar to the previous year. China label and English label products are expected to recover gradually, supported by two new China label products and an updated a2 Platinum product.


The company still expects group revenue and earnings before interest, tax, depreciation and amortisation to grow. It forecast revenue growth in the middle single digit percentage range and an underlying earnings margin of about 15 percent. The balance matters because it shows that growth in liquid milk, other nutrition products and new markets is expected to offset a slow formula recovery.


Management expects revenue and earnings to be weighted toward the second half of the financial year. First half revenue is expected to be slightly lower than a year earlier, while first half underlying earnings are expected to be materially lower. For retailers and suppliers, this means the recovery plan depends on sustained improvement rather than one strong shipment period.


Marketing must rebuild demand as well as awareness


The company plans to increase marketing, particularly in the first half of the year. The commercial task is not only to tell consumers that supply has returned. It must persuade parents and retail partners that availability will remain reliable, while supporting new products without confusing the core range.


China remains a difficult formula market because birth rates, regulation, domestic competition and channel economics all influence demand. a2 Milk sells China label products through domestic online and mother and baby retail channels, while English label products use cross border ecommerce and other channels. Recovery can therefore move at different speeds across the portfolio.


The company's official description of its Greater China business identifies the region as its largest market and a core growth engine. That concentration makes the current recovery important beyond a single product line. It affects factory planning, inventory, retailer support and the amount of promotional spending required to win users back.


The Pōkeno transition adds execution risk


a2 Milk is also moving a2 Platinum production to its Pōkeno operation in New Zealand. The company expects about NZ$15 million in transformation costs during the 2027 financial year, including roughly NZ$5 million for integration and NZ$10 million for supply chain and market transition work.


The company expects no further transformation costs in the following financial year, but the near term work increases the importance of a controlled transfer. Infant formula production requires consistent quality, regulatory compliance and careful inventory management. A transition that improves long term control can still create short term risk if production, registration or market timing slips.


What could change the outlook


The company explicitly identified the speed of the China recovery, competition, export and import requirements, foreign exchange, milk prices and product supply as material risks. It also said import requirements are still affecting a2 Genesis, so not every planned product is moving freely through the market.


Investors and industry partners should watch three indicators. The first is whether China label sales continue improving beyond the current 50 percent level. The second is whether the added marketing converts into repeat purchases rather than temporary trial. The third is whether the Pōkeno transition proceeds without another availability gap.


The latest release is therefore a recovery update, not a declaration that the disruption is over. Supply has improved and the company expects group growth, but infant formula sales are still forecast to remain roughly flat for the year. The next evidence must come from sustained consumer demand and dependable product availability.


Cover image: original editorial illustration created for Agrilinkage. It represents infant formula manufacturing and export logistics and does not depict a specific company facility or shipment.

Recent Posts

See All

Comments


bottom of page